University of the Pacific

Scholarly Commons
University of the Pacific Theses and
Dissertations

Graduate School

2019

Glycemic Control in a Type I Diabetic Athlete: Recommendations
for Athletic Trainers in Management, Athlete Care, and
Performance
Megan Whyte
University of the Pacific

Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds
Part of the Sports Sciences Commons, and the Sports Studies Commons

Recommended Citation
Whyte, Megan. (2019). Glycemic Control in a Type I Diabetic Athlete: Recommendations for Athletic
Trainers in Management, Athlete Care, and Performance. University of the Pacific, Thesis.
https://scholarlycommons.pacific.edu/uop_etds/3605

This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been
accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of
Scholarly Commons. For more information, please contact mgibney@pacific.edu.

1
GLYCEMIC CONTROL IN A TYPE I DIABETIC ATHLETE: RECOMMENDATIONS FOR
ATHLETIC TRAINERS IN MANAGEMENT, ATHLETE CARE, AND PERFORMANCE

by

Megan E. Whyte

A Thesis Submitted to the
Graduate School
In Partial Fulfillment of the
Requirements for the Degree of
Master of Arts

College of the Pacific
Health, Exercise, and Sport Sciences

University of the Pacific
Stockton, California
2019

2
GLYCEMIC CONTROL IN A TYPE I DIABETIC ATHLETE: RECOMMENDATIONS FOR
ATHLETIC TRAINERS IN MANAGEMENT, ATHLETE CARE, AND PERFORMANCE

By
Megan E. Whyte

APPROVED BY:
Thesis Advisor: J. Mark VanNess, Ph.D.
Committee Chair: J. Mark VanNess, Ph.D.
Committee Member: Christine Lo Bue-Estes, Ph.D.
Committee Member: Manuel De Alba, MAT, ATC
Department Chair: J. Mark VanNess, Ph.D.
Dean of Graduate School: Thomas Naehr, Ph.D.

3
DEDICATION

This manuscript is dedicated to my parents, Buck and Melanie, who have unconditionally
supported me through this journey. Not only did you support my decision to move across the
country, but you also decided to make the drive with me and the contents of my entire apartment.
I will never be able to thank you enough for everything that you have done for me for the past 25
years. Of course, I can’t forget about my Uncle Dorm, as he has supported me just as
unconditionally as my parents.
This manuscript is also dedicated to Dr. Mark VanNess who never gave up on me during
these two years. Your constant encouragement and support kept me going, even when all I
wanted to do was quit and sleep for a few years. You were the light at the end of the tunnel
during my career at Pacific and I will be sure to tell stories about you for years to come.
To Christine: I would have never finished my manuscript if you did not check in on me
every day. You pushed me and challenged me in ways that I did not know I needed, or wanted,
and I am forever grateful to you. This manuscript would not be what it is without your input,
advice, and vent sessions. To Manny: without your support and encouragement from behind the
scenes I would not have been able to survive the rough days. Thank you for being a second set of
eyes, and the voice of reason when I needed it most. To Peter: without you and your banana this
entire manuscript would not exist. You made this project interesting and I enjoyed working on it
because I knew I would be working with you. I will cherish your friendship for years to come,
and I am honored that you were willing to work with me throughout this project.

4
ACKNOWLEDGEMENTS

There are many people who deserve to be acknowledged for their roles in my education,
career, and life. Carol Swaney, without you I would not have become the athletic trainer I am
today. You renewed my passion for this profession, and I aspire to one day be the clinician,
preceptor, and wonderful human being that you are. Ross Watson, you always cheered me on in
the background, and made sure you were able to be there when I needed the most support. Who
knew we would come so far after goofing off on a treadmill and a wheelchair? Myka, Jessica,
Maddie, Madeline, Levent, Philip, Orlando, Ralene, and Caity – I wish I could thank all of you
individually for your support during this process, but that would take too long. You all mean
more to me than words will ever be able to express and without you all there would have been no
sunshine during this last year of work. The many late nights full of karaoke, coffee, and snacks
kept me running when I was on empty. To Dr. Courtney Jensen, thank you for allowing me to
use your office while you were away, and for always making me laugh when I needed it the
most. I will always remember your kindness and generosity. Last but not least, I have to thank
Molly Bourne. Your kind words, loving friendship, and solid support helped keep me on track
when I would get distracted or want to take a break. Your unwavering dedication to making me
realize my full potential will stay with me for the rest of my life, and I love you so much for that.

5
GLYCEMIC CONTROL IN A TYPE I DIABETIC ATHLETE: RECOMMENDATIONS FOR
ATHLETIC TRAINERS IN MANAGEMENT, ATHLETE CARE, AND PERFORMANCE

Abstract

by Megan E. Whyte
University of the Pacific
2019

Type I diabetes in athletes is a relatively rare condition and as a certified athletic trainer it
is critical to know how to manage all aspects of this disease in an athlete. Current National
Athletic Trainers’ Association (NATA) guidelines exist for developing a basic plan for
management and care of an athlete with Type I Diabetes, but there is room to improve current
guidelines, using evidence-based practice. Purpose: to address: medical management of a type I
diabetic athlete as a case study, obtain first person observations from the athlete’s perspective,
and provide additional evidence based practice recommendations to athletic trainers based on the
findings. Methods: case study narrative with one subject, a 22-year-old male collegiate soccer
player was performed. Data were collected via open-ended questionnaire, open-ended interview,
and subject’s submission of pertinent medical information and records. Results: The NATA
Position Statement on Type I Diabetes and other peer review articles informed this study. While
NATA guidelines created a good general baseline for how to approach providing diabetic athlete
care; additional recommendations are suggested based on the findings of this case study. These
recommendations include: Creating safe pre-participation blood glucose ranges to prevent
hypoglycemia during exercise, establishing greater knowledge about the technology the patient
uses, what medical supplies the patient should be responsible for versus the athletic trainer,
developing a relationship with the patient’s endocrinologist or primary care physician, and
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administration of insulin by an athletic trainer. These additional suggested recommendations
inform athletic trainers to attain a better understanding of how to manage and care for a patient
with Type I Diabetes, and increase the likelihood of both streamlining patient care and
preventing metabolic crisis.
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Chapter 1: Introduction
Diabetes
Type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), is caused by the
inability of the pancreas to produce sufficient levels of the hormone insulin, which helps regulate
blood glucose levels. Insulin is released by the beta cells of the pancreas into the blood stream
when glucose levels go up, such as after eating. Insulin helps glucose enter the body’s cells
where glucose can be used for energy or stored for future use. With type I diabetes the beta cells
of the pancreas do not or cannot respond normally to produce insulin when glucose is present.
This pancreatic impairment results in an abnormal metabolism of carbohydrates, which leads to
elevated levels of glucose in the blood. Thus, exogenous insulin therapy is necessary to prevent
hyperglycemia, or high blood sugar. Insulin deficiency often becomes symptomatic in children
between the ages of 9 and 16 and is a life-long disease with no known cure. Type 1 diabetes is
less common than type 2, or non-insulin dependent diabetes mellitus (NIDDM), with only 5-10%
of all diabetes cases being type 1. While the cause of the disease is not fully understood, one
main factor involves an autoimmune destruction of the beta cells in the pancreas that result in the
marked and progressive inability of the pancreas to secrete insulin. While there is no cure for
type 1 diabetes, it is manageable with insulin therapy (Fahey, Stallkamp, & Kwatra, 1996).
Purpose of Study
The current case study examines glycemic control, eating and exercise habits to provide
more complete and specific recommendations for athletic trainers dealing with type I diabetic
athletes based on current NATA recommendations.
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Limitations
Limitations of this study include:
1. This was a case study based on one subject who is male; females may have additional
gender specific concerns to consider/address.
2. The subject is a post-pubescent male.
3. This study involved a highly aerobic athlete and recommendations might differ for
other types of athletes, based on primary mode of exercise/metabolic pathway used.
4. The data collected observes only one season and one off-season, thus no year to year
comparison is possible.
5. This study was not trying to figure out how to attain glycemic control as the subject
had already established good glycemic control.
Delimitations
Delimitations of the study include:
1. Limited period of time to collect data
2. Only one diabetic athlete in the university athlete population, during the limited time
period to collect data.
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Chapter 2: Review of Literature
History
1900-1939. Insulin was discovered in 1910 by Sir Edward Albert Sharpey-Schafer, an
English physiologist who was studying the pancreas. Six years later, Elliot Joslin MD published
the first edition of The Treatment of Diabetes Mellitus. In 1921 Frederick Banting, MD, and his
student assistant Charles Best, MD, were able to successfully extract insulin from dog pancreases
and inject it into dogs whose pancreases had been removed. Banting and Best observed a
reduction in blood sugar levels in dogs without pancreases, making this the first successful
insulin transplant experiment. This insulin extract was purified so it could be used in humans
and two years later, in 1923, Eli Lilly and Co. began commercial production of insulin. Banting
and J. J. R. Macleod were awarded the 1923 Nobel Prize in Physiology or Medicine, but the
contributions of Best and James Collip have also been acknowledged as crucial in the discovery
of insulin. Due to the work of Eli Lilly and Co. manufacturers were able to produce sloweracting insulins over the next few years, and in 1936 Novo Nordisk developed protamine insulin.
This was monumental as slower acting insulin allows for a slower decrease in the blood sugar
levels preventing the “crash” most experience after eating a high carbohydrate meal
(Association, 2018).
1940-1947. In 1940 The American Diabetes Association was founded to help combat the
increasing amount of cases of diabetes and to address the comorbidities that develop due to the
disease. In 1949 it was discovered that insulin works like a key to transport glucose into the cells
when glucose levels in the blood are too high. Until 1959 there were no real classifications of
diabetes, but radioimmunoassay technology uncovered that a percentage of the population with
diabetes was still able to produce their own insulin. This led to the identification of IDDM and
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NIDDM. In 1961, 38 years after commercializing production of insulin, Eli Lilly and Co. began
producing glucagon, a hormone whose main function is to raise blood sugar levels, as a
treatment for severely low blood sugar levels. Having a readily available form of glucagon via
injection could potentially assist in reducing hospitalizations from hypoglycemia. As medical
procedures continued to advance, the first successful pancreas transplant was performed at the
University of Minnesota Hospital in 1966. Insulin receptors on the cell surface were discovered
in 1971 but were not identified as GLUT-4 receptors until 1989. In 1972 the relationship
between blood vessel disease and hyperglycemia is reported which established correlation
between chronic hyperglycemia and comorbidities of diabetes. In the last few years of the
1970’s, a test was developed to measure glycosylated hemoglobin (HbA1C) which became the
gold standard for measuring long-term diabetes glycemic control, and the National Diabetes Data
Group develops a new classification system. The new classifications were insulin-dependent,
non-insulin dependent, gestational diabetes, and diabetes associated with other syndromes or
conditions (Association, 2018).
1980-PRESENT. In 1983 a link was discovered between hypoglycemia and brain
metabolism. Then in 1984 the insulin molecule was identified to be the target of the
autoimmune response in individuals with type I diabetes. Along with the identification of insulin
as a target of the immune system, the glutamate decarboxylase (GAD) protein was also later
identified to trigger a progressive autoimmune response that leads to diabetes. In 1989 the
American Diabetes Association published its first standards of care to help guide physicians
through the treatment of diabetes. The early 1990’s brought about significant changes to the way
diabetes was managed. In 1993, the Diabetes Control and Complications Trial (DCCT) showed
that regulating blood glucose levels, and keeping them within the normal ranges as much as
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possible, resulted in a smaller likelihood of the onset and progression of eye, kidney, and nerve
diseases caused by diabetes. The trial also helped show that any long-term normalization of
blood glucose helps reduce the chance of the onset of the comorbidities, even if the patient has a
history of poor glucose regulation. In 1997 the fasting glucose level for diagnosing diabetes was
lowered from 140 mg/dL to 126 mg/dL which goes along with the results of the DCCT. In the
early 2000’s the American Diabetes Association created a definition for prediabetes using
impaired fasting glucose (IFG) defined as fasting blood glucose of 100-125 mg/dL, and/or
impaired glucose tolerance (IGT) defined as a glucose level of 140-199 mg/dL two hours after
drinking a large bolus of glucose. Another marker added to inclusion for prediabetes was an
HbA1C level of 5.7%-6.4% (Association, 2018).
Technology
In 1949, Becton Dickinson and Co. also began production of standardized insulin
syringes based on designs from the American Diabetes Association. The next big breakthrough
in diabetes care came in 1953, when tablets and test strips for urine testing became widely
available. This breakthrough was important as testing for glucose in the urine allowed for early
identification of kidney damage, which often does not show symptoms until damage is
significant and often irreversible. As technology progressed, testing strips not only became more
readily available, but also in 1964 strips were introduced that allowed diabetic patients to test
blood glucose levels by comparing the color spot on a blood glucose test strip with standardized
color blocks. This helped patients understand glycemic control ranges more accurately
(Association, 2018). Technology advanced again with the introduction of the first glucose meter
by the Ames Company in 1970, called the Ames Reflectance Meter. This meter consisted of a
needle that “indicated the intensity of blue light reflected from a paper strip.” The meter then
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gave a number that correlated to the glucose levels in the blood the paper strip was exposed to.
This first meter weighed about three pounds and was originally marketed to physicians and not
patients (Aleppo, 2018). It wasn’t until Richard Bernstein acquired a machine and used it to map
out the daily fluctuations in his blood glucose levels that companies began to realize patients
could use this technology to better monitor their own blood glucose levels. As glucose monitors
continued to evolve, the Biostator was developed in 1974, creating the first closed loop insulin
infusion, enabling the production of continuous glucose monitors (Association, 2018). The
Biostator works by having a small amount of venous blood continuously flowing through the
machine which can analyze the blood glucose concentration (Continuous Glucose Monitoring |
NIDDK, 2018). The Biostator feedback system was also able to note the amount of insulin or
dextrose required to normalize the blood glucose concentration. The Biostator system was a
giant leap forward in allowing a patient to go about their normal daily routine while on the
machine which allowed for better planning and creating individualized medical regimes for type
I diabetics. Although the first insulin pump was technically created in 1963 by Dr. Arnold
Kadish, these devices were incredibly large and were designed to be worn as a backpack which
made them quite impractical. It wasn’t until 1976 that a smaller, more wearable device was
created, and in 1978 portable insulin pumps were introduced to the market. In 1980 the concept
of basal-bolus insulin was introduced and allowed for “intensive insulin therapy” to be used in
the clinic as a treatment for type I diabetes (Association, 2018).
Management
Management of type 1 diabetes is possible through administering insulin shots, using an
insulin pump, checking blood glucose levels often throughout the day, following a healthy and
balanced diet, and exercising regularly (Fahey, Stallkamp, & Kwatra, 1996). As technology
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advances, it is becoming increasingly more common to see a type 1 diabetic use an insulin pump
to control the flow of insulin. An insulin pump is a machine that will deliver insulin to the
wearer as it is programmed with variable potential settings depending on the method of delivery
desired. Insulin can be delivered via a “drip feed” which is a continuous injection throughout the
day, but the pump can also deliver a large dose or bolus, when needed (Aleppo, 2018). Along
with an insulin pump, most type 1 diabetics will also have some form of continuous glucose
monitor that can be included as a component of an insulin pump or may be a completely separate
device. A continuous glucose monitor is a small device attached to the abdomen or upper arm
that measures then wirelessly sends the glucose readings to a monitor, which can be as simple as
an app on your smartphone (Continuous Glucose Monitoring | NIDDK, 2018). The clear goal of
managing diabetes in an athlete is avoiding hypo- and hyperglycemic episodes during and after
activity. It is imperative that the athletic trainer discuss a management plan with their athlete,
and check in with this athlete before and after each practice; including but not limited to weight
lifting, practice, games, and conditioning. Although the American Diabetes Association
recommends an ideal range for blood glucose levels, it is important to speak with the individual
athlete and determine the ideal range that their endocrinologist has provided them (Brooks,
Fahey, White, & Baldwin, 2000).
Exercise and Diabetes
Exercise is a healthy part of management of type 1 diabetes; however, exercise affects
insulin levels and it increases the risk of hypoglycemia. Skeletal muscle helps with glycemic
control and metabolic homeostasis and is where glucose is predominantly stored when insulin is
active. Non-insulin dependent glucose uptake (NIDGU) is the main way skeletal muscle helps
with glycemic control and is the uptake of glucose by cells when insulin is not present, primarily
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when muscle contracts. Muscles utilize glucose as the main source of fuel during the beginning
stages of exercise. Exercise increases the ability of GLUT-4 receptors to translocate to the cell
surface allowing glucose to flow into the cell. This increased translocation continues even after
exercise has ended, and exercise also increases the number of GLUT-4 receptors that are present
in the skeletal muscle cells. Exercise additionally increases the amount of skeletal muscle. An
increased presence of GLUT-4 receptors and their activity due to the aforementioned effects of
exercise allows for better uptake of glucose by the cells, thus reducing the amount of insulin
required. Given that there is a high rate of ATP turnover during muscle contraction, exercise
increases AMPK phosphorylation and enzymatic activity in an intensity-dependent manner. As
soccer is a relatively high intensity activity, glucose is the main source of fuel and will be
derived from hepatic glucose production or muscle glycogenolysis. In skeletal muscle, acute
AMPK activation suppresses glycogen and protein synthesis but promotes glucose transport and
lipid metabolism. As muscle glycogen is depleted, a balance develops between glucose
production and glucose uptake by exercising muscle. This causes insulin secretion to decrease as
muscle glucose uptake increases due to exercise stimulating (rather than insulin stimulating) the
translocation of GLUT-4 receptors to the cell surface. A slight increase in catecholamines
combined with the decrease of insulin promotes lipolysis in exercise, permitting the use of free
fatty acids as fuel and later gluconeogenesis. Once exercise stops, insulin levels rapidly increase
in response to high blood glucose levels and removal of circulating catecholamines. This results
in hyperglycemia and hyperinsulinemia combining to create ideal homeostatic metabolic
conditions for the replenishment of muscle glycogen (Brooks, Fahey, White, & Baldwin, 2000).
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Glycemic Disorders
The increase in glucose uptake during exercise creates an issue for an athletic trainer
providing care for a type 1 diabetic athlete. When athletes exercise, the physical activity lowers
blood glucose levels as the muscles are using stores of glycogen as fuel. As the glycogen stores
are depleted blood glucose will naturally drop, meaning the athlete will need to increase their
glucose levels before or potentially even during exercise, so that they don’t fall into a
hypoglycemic state. If blood glucose falls below 70 mg/dL the person is considered
hypoglycemic. When blood glucose levels get this low, signs and symptoms such as
tachycardia, sweating, palpitations, hunger, nervousness, headache, trembling, and dizziness can
occur. If blood glucose levels continue to fall and get below 54 mg/dL, immediate medical
intervention is required. At this level signs and symptoms will include blurred vision, fatigue,
difficulty thinking, loss of motor control, aggressive behavior, seizures, convulsions and loss of
consciousness which can eventually lead to a diabetic coma. Glycemic control during exercise is
more problematic for a diabetic athlete as they are out on a playing field and do not always have
access to high glycolytic sources to keep their glucose levels stable (Kirk, 2009). On the
opposite side of the spectrum, though it is rare, if an athlete’s blood glucose levels are too high
before beginning exercise, there is a potential that an even higher spike may occur, leading to
hyperglycemia (Jimenez, et al., 2007). If one is in a state of hyperglycemia for an extended
period of time, negative side effects such as: cardiovascular disease, nerve damage, kidney
damage, eye damage, and skin conditions can occur. A person is considered hyperglycemic
when blood glucose levels reach 250 mg/dL or higher. If blood glucose levels continue to rise
and get above 300 mg/dL ketoacidosis begins to occur. The patient can experience excessive
thirst, frequent urination, nausea and vomiting, abdominal pain, weakness or fatigue, shortness of
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breath, fruity-scented breath, and confusion. Consequently, a majority of the symptoms of
ketoacidosis are what is used to make the diagnosis of diabetes. The patient will most likely
present to the emergency room with many of these symptoms leading practitioners to test blood
glucose levels as well as take a urine sample to test for high ketone levels in the urine. The
normal ranges for blood glucose levels range from 90 to 140mg/dL, but this range will vary from
person to person depending on a multitude of factors including age, gender, activity level, and
any comorbidities they may have (Medicine, 2001).
Why Is This Important?
There are some questions that athletic trainers may not even know to ask their diabetic
athlete. Outside of using resources such as the “National Athletic Trainers’ Association Position
Statement: Management of the Athlete With Type 1 Diabetes Mellitus” it is still important to
know how pancreas function is impaired, how blood glucose levels change with exercise and
factors such as illness, fatigue, sleep disturbances, stress, etc., questions to discuss with the
athlete, and ways to help limit episodes of hypo- and hyperglycemia.
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Chapter 3: Methodology
The methods of this study were approved by the institutional review board of The
University of the Pacific. Prior to participation, the subject completed and signed an informed
consent form. The sample population of this study was an undergraduate male soccer player
with type I diabetes. Participant was selected based on the criteria of being a collegiate athlete
with type I diabetes.
Data were collected through interviews with the participant where his journey with
diabetes was discussed and daily normative values were reviewed. All data provided by the
subject were blinded of all identifying information and kept in a locked cabinet behind a locked
door, and/or in a password protected computer.
The subject was selected out of convenience. There was a pre-established professional
relationship between the lead researcher and the subject. The lead researcher was the certified
athletic trainer for the subject and therefore developed a professional medical relationship with
the subject. Information was gathered through a semi-structured interview with medical followup. Primarily an interview was conducted, but medical information in collaboration with the
subject was also gathered. Pertinent information also included output data from his CGM and
any pertinent laboratory data such as HbA1C.
All information gathered through the interview and any accompanying medical
information aided in getting a full history of the patient, his condition, and his journey through
life with diabetes. The researcher was also interested in his experiences and his personal
management techniques and evaluated how successful he has been based on his glucose levels
and HbA1C. This information was combined with current literature to create guidelines for
athletic trainers to use when they encounter an athlete with type I diabetes.
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The following interview questions were asked of the subject to help guide the discussion:
1. When did you find out you have diabetes?
2. How did you find out?
3. How did you learn how to manage your diabetes? (did someone teach you or give you
techniques, did you learn to read your body’s signals, etc.)
a. How long have you had your insulin pump?
b. How long have you been using a continuous glucose monitor?
4. How long have you been an athlete?
5. Tell me about your dietary habits.
6. How do you stay physically active when not playing soccer?
7. Any other pertinent medical information?
a. History of any severe illness?
8. What is your perspective on being a person with diabetes?
9. What is your perspective on being an athlete with diabetes?
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Chapter 4: Results
Subject Demographics
A 22-year-old male, type I diabetic, collegiate soccer player who was 72 inches tall and
weighed 175 pounds participate in the case study. His HgA1C was 6.1 at the time of the study,
body composition of 9.08% body fat using both hydrostatic weighing and skinfold calipers, and a
VO2max of 58mL/kg/min. With the results from his VO2max testing, the subject falls into the
category of “good”. There is only one category above this, that being “excellent” (Medicine,
2001). This result is to be expected of a high-level athlete and helps show the level of physical
fitness of the subject. The subject has been playing soccer since he was a child and began
playing competitively in the fourth grade. When not playing soccer, he remains physically active
by going to the gym for cardio and weightlifting. He states that maintaining a relatively
consistent exercise schedule is helpful for maintaining glycemic control, and missing as little as
three days of exercise means he will have to adjust his basal insulin rates and carb-to-insulin
ratios (Personal Interview with Subject, 2019).
Subject History
The subject was diagnosed at age 12 in seventh grade, about ten years ago. Subject states
that he felt constantly thirsty, became very lethargic and was always tired although he did not
have any severe illnesses before his diagnosis. He began to have a burning sensation in the back
of his throat which he now attributes to being in ketoacidosis. He began to lose a lot of weight
and this is when his family began to notice the changes. His uncle is a type I diabetic, and his
grandfather is a physician, and they both noticed the symptoms and decided to test his blood
glucose levels. The machine couldn’t read his actual blood sugar and just came back with a
result of “600+”, and when his sugar was tested again in the hospital it read over 800 mg/dL. He
was hospitalized for a week after his diagnosis where his blood glucose was brought down into
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the normal range of about 120 mg/dL and his ketones and diabetic ketoacidosis symptoms were
eliminated. During this time, he was also educated on what exactly diabetes is, how to count
carbs, warning signs of hypo- and hyperglycemia, how blood glucose levels may vary with
exercise and many more topics. He was also taught how management of diabetes varies from
person to person and will take time, experience, and practice to get better.
Patient Introduction to Management
After the first year of learning to manage his carbohydrate intake and insulin usage, the
subject was given an insulin pump. He was told to wait at least a year because his doctor
preferred he not rely too heavily on a pump and learn to manage diabetes first and the pump
second. In the early years of a diagnosis it is important for the patients to understand their own
insulin to carbohydrate ratios and how they may need to adjust throughout the course of a day.
The subject also admitted being “a little scared” of the pump in the beginning “because having
something like a little needle attached to me all the time seemed a little intimidating” (Personal
Interview with Subject, 2019). However, after he made the switch from the insulin pens to the
pump, he states he liked the pump more even though it took some time to adjust. Five years
prior to this case study, the subject got his first continuous glucose monitor (CGM) and admits
he was intimidated by the CGM at first too. He states there was a large adjustment period,
although he does not remember the exact amount of time, as the CGM was uncomfortable, fell
off a lot, and it was not as accurate as he would have liked so he ultimately stopped using it for
about a year. After the CGM was redesigned and a new model was introduced, he tried it again
and has continually used one.
Patient Perspective
When asked about how he views himself as a person with type I diabetes the subject stated,
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“My diabetes is something that I have completely accepted and embrace about myself. I
credit it with teaching me to push myself and not let anything stop me from what I want
to accomplish. This I learned from persevering and continuing to play sports and even
making it to the D1 level despite being a type one diabetic. I am very outward about
having diabetes and even identify myself with the caduceus symbol since I wear the T1D
alert bracelet on my wrist and carry that sign with me everywhere I go” (Personal
Interview with Subject, 2019).
When asked about how he views himself as an athlete with type I diabetes the subject stated,
“I see myself as an opportunity to be a sort of inspiration to people. I know that while I
see diabetes as a huge learning opportunity, others see it as an impassible obstacle. I
want to show others that although diabetes is a challenge that one will have to carry with
them for every second of the rest of their lives, they can still accomplish whatever they
want to. There are many people that struggle with T1D; whether it be shortly following a
diagnosis, years after it, or intermittently throughout life, I think T1D is something that
people need help and support with” (Personal Interview with Subject, 2019).
Data Collection
Output data were collected from the subjects CGM and insulin pump over a 10-day
period in season, and another 10-day period during the off-season. The data included blood
glucose levels measured every five minutes over a 24-hour period, manual finger sticks taken
throughout the day, carbohydrates entered into the insulin pump, and any insulin boluses given.
The CGM automatically generates a graph of the blood glucose levels, and the manual finger
sticks were recorded and also used to create a graph. The implications for output data and graphs
are discussed below, and the graphs are in Appendix A.
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Chapter 5: Discussion
Blood Glucose
After reviewing the subject’s output data from his continuous glucose monitor, insulin
pump, and daily finger sticks, daily trends in blood glucose levels were readily identifiable.
According to the subject, his endocrinologist wanted his blood glucose levels to remain in the
range of 70-120mg/dL, and his HbA1C to fall between 6.0 and 6.5. A normal range for HgA1C
is 4.0-5.6, with 5.7-6.4 showing a higher chance of getting diabetes, and finally 6.5 and higher
showing the patient has diabetes (Brooks, Fahey, White, & Baldwin, 2000). The subject has a
low HbA1C for a patient with diabetes, at only 6.1, which goes to show how well he manages his
disease.
While in season, the subject consistently had an average blood glucose level that fell in
the range of 80-150mg/dL according to the manual blood glucose readings he took each day.
However, when looking at his continuous glucose monitor output, it is observed that he had
multiple times where he fell below 70mg/dL, even getting as low as 40 mg/dL. He also
consistently had high blood glucose levels, between 150mg/dL and 250 mg/dL, around seven
a.m., two p.m., and ten p.m. These spikes are not unexpected as they occurred after he had eaten
and administered his insulin but was still waiting for the insulin to take effect. His multiple 8-15
daily manual blood glucose finger sticks showed very widespread and inconsistent values
because these data points present only a partial picture of what his levels are throughout the
course of a day. The finger stick data, unlike CGM data, do not tell you if the blood glucose
value is rising or falling, which is an important piece of information relevant to appropriate
medical management of the diabetic.
During the off-season he consistently had blood glucose levels in the range of 80130mg/dL. He consistently had high blood glucose levels around seven AM and nine PM which
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occur after he has eaten breakfast or dinner. Although his finger sticks showed more regularity
and consistency throughout the day, as compared to finger stick data from the in-season
collection period, this is the opposite of what the data from his continuous glucose monitor
showed. There are multiple days where his blood glucose levels were above 300 mg/dL, even
exceeding 400 mg/dL at one point, which was not demonstrated by the finger sticks. There were
also multiple days where his blood glucose levels fall below 60 mg/dL, even reaching as low as
40 mg/dL. The outputs generated by the continuous glucose monitor are important to have,
understand, and utilize, as they show the complete and timely picture of what the diabetic goes
through during the course of a day. The use of the CGM also allows for the identification of
circadian trends, which will vary patient to patient. Without the information available from the
CGM, the data suggests that the subject has more consistent glycemic control out of season than
in-season, however this is backwards (see Appendix A). The graphs generated from the CGM
data are important for the athletic trainer to utilize and understand as they give a complete picture
of how an athlete is truly managing their glucose levels. Rather than just assessing average
glucose values at designated times, or looking at a scatter plot of isolated glucose values, seeing
all of the peaks and valleys on the graph provides context and vastly more useful and actionable
data for the athletic trainer. Additionally, providing the slopes of the increases and decreases in
blood glucose values demonstrates the rate of the glucose shifts for the athlete, which is a critical
safety factor for the athlete. Appropriate use and understanding of the CGM data lets the athletic
trainer understand what the normal for their athlete is and allows the athletic trainer to identify
why their patient may be having an issue one day, based on objective data as opposed to a guess.
If an athlete comes to the athletic trainer stating s/he is feeling sick or lethargic, the athletic
trainer can use the CGM graph to help make an appropriate differential diagnosis determining if
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the athlete is acutely ill, having and acute glycemic issue, is tired from the amount of school
work and athletic activity they have been doing, or any combination thereof.
During the out-of-season assessment period, when the subject’s blood glucose exceeded
400mg/dL, he admitted that he had been drinking alcohol that night and clearly did not manage
his blood glucose as well as he usually does. However, events like this are not uncommon with a
type I diabetic and can be attributed to factors like: eating cake, ice cream, or cake and ice cream,
or acute illness or stresses. Diabetics are people too, and sometimes being responsible about
glycemic management takes a back seat to living in the moment and enjoying one’s life. While
in-season the subject was stricter with his diet and the team as a whole observes a “dry season”
policy where no alcohol may be consumed. He states that he was completely compliant with dry
season but he allowed himself to “be a college student in the off season” (Personal Interview
with Subject, 2019).
Additional Recommendations
Current guidelines for athletic trainers are established but are general, and they typically
require the athletic trainer to do extensive additional research and planning on their own.
Accepted management currently includes developing a diabetes care plan for practices and
games with the athlete. This can include but is not limited to, monitoring blood glucose levels,
insulin therapy guidelines, a list of any and all other medications taken, guidelines for
hypoglycemia recognition and treatment, guidelines for hyperglycemia recognition and
treatment, and emergency contact information. Noticeably absent from the guidelines are
recommendations to: discuss with the endocrinologist or primary physician the treatment plan of
care, learning the method of insulin delivery including both hardware and software, if the patient
uses a pump, and other co-morbidities and health challenges. When monitoring blood glucose
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levels, it is important to determine frequency of testing, and appropriate pre-exercise levels and
values and what to do if the athlete is outside of those ranges. The guidelines do not give
recommendations on the number of blood glucose checks per day, so this must be established
with the athlete at the beginning of the season. The subject in this study was exceedingly
compliant and performed manual checks between eight and fifteen times per day and this still
gave an incomplete picture of how his blood glucose was managed.
The insulin therapy guidelines created need to include the type of insulin used, dosages
for your athlete, any adjustment strategies for planned activity types, and insulin correction
dosages for high blood glucose levels. What the current guidelines don’t include is what an
inappropriate blood glucose level pre-exercise is, and what to do to combat an abnormal value
when it does occur. It should be recommended that the athlete not be allowed to participate if
their blood glucose remains below 100 mg/dL 30 minutes before participation despite food
intake, unless demonstrated that blood glucose is rising according to CGM data. As blood
glucose levels fall during the initial stages of exercise, the athlete’s blood glucose may fall too
low and s/he will need to eat or drink a high glycolytic item and remove themselves from play
for the day. It is important to note here, that a majority of the current research recommends
athletic trainers not provide an athlete with insulin; it should only be administered by the athlete
or a medical doctor who has training to deal with diabetic patients. However, if the athletic
trainer has met with the athlete’s endocrinologist, and is trained on how to properly administer
insulin in an emergency scenario, then it should be recommended that the athletic trainer have
the ability to administer insulin in an emergency situation when the athlete is unable to
administer it themselves. This will entail the athletic trainer knowing how to check data on a
pump if the athlete uses a pump, manually testing the blood glucose through finger stick if there
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is no pump, learning how to measure out units of insulin if manually injecting, where to
administer that insulin, or learning how to administer a bolus of insulin on a pump, and
determining the correct bolus to administer if it has to be calculated (an insulin pump will
typically recommend a specific bolus to deliver, but it needs to be calculated for a patient that
isn’t utilizing a pump). Having the athletic trainer deliver the medically necessary insulin in
times of hyperglycemic crisis will reduce the amount of time the athlete spends in the
hyperglycemic episode, instead of waiting for emergency medical services to arrive, transport the
patient to an emergency department, triage, and finally administer insulin treatment. Working
with the athlete’s endocrinologist while determining the appropriate plan of care allows for safe
execution of insulin administration in an effort to quickly lower the blood glucose while
minimizing the risk of sending the athlete into a hypoglycemic episode.
Guidelines for recognition and treatment of hypo- and hyperglycemia must include
prevention, signs and symptoms, treatment, use of glucagon for hypoglycemia, and treatment for
ketosis with hyperglycemia. These guidelines should be thorough, but simple enough for anyone
to understand in an emergency. Emergency contact information should include parent/guardian
phone numbers and a copy of written consent for medical treatment if required when dealing
with minors. It is also crucial that the athlete ensure they have a medical alert tag on their person
at all times. Along with the diabetes care plan, it is important for the athletic trainer to know
what to pack in their kit. At minimum it is recommended that the athletic trainer pack: A copy of
the diabetes care plan, blood glucose monitoring equipment and supplies, glucagon injection kit,
supplies for urine or blood ketone testing, a small sharps container, spare batteries, spare infusion
sets and reservoirs for insulin pumps if applicable. While guidelines state the athletic trainer
should carry these last items, they are prescription and expensive and it should be, and is more
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pragmatic that it is the responsibility of the athlete to carry these items. Note, that no mention of
additional insulin is addressed in current guidelines, and spare infusion sets and insulin
reservoirs, without insulin are useless. Most diabetics do not carry addition insulin as it has to be
refrigerated while stored. So, if the current recommendation to carry these items remains, the
issue of additional insulin should be addressed. It is important to establish in the care plan if the
athlete is going to carry a kit on them at all times where they can hold all of the supplies they
need. If this is the case, this strategy will reduce cost for the athlete, and s/he will not need to
provide extra supplies to their athletic trainer and can just keep one kit. A logical strategy could
be that the athletic trainer keeps the athlete’s kit on the sidelines with the athletic trainer during
practices and games and returns it to the athlete at the completion of activities for the day. High
glucose containing foods and/or drinks with a high glycemic index should also be carried by the
athletic trainer. Some appropriate examples of high glycemic index foods include fruit snacks,
glucose tablets, sugar packets, and fruit purees. Examples of high glycemic index fluids include
orange juice, fruit punch, and non-diet soda. It is also important to know the timing of
administration of the high glycemic item, whether it is before a practice versus before a game. It
would be inadvisable to give an athlete a carbonated beverage right before they participate in a
practice or game due to potential gastrointestinal distress, so fruit juice or a fruit puree would be
the better choice. However, if the athlete has at least three to four hours before their athletic
event, a carbonated beverage would be fine.
In order to safely monitor their glucose levels, the athlete may have to remove themselves
from play, test their blood glucose, consume a high glycolytic food or drink or take insulin if
they are hyperglycemic. Then a decision will need to be made on whether or not the athlete can
return to play depending on how quickly their blood glucose levels normalize. As previously
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discussed, this entails the athlete bring an onsite kit with all necessary equipment to assess blood
sugar that is available at both practices and games. There are other potential complications of
being an athlete with type 1 diabetes such as metabolic demands for carbohydrate and fat that
must be met to maximize training effects and maintain both athletic performance and health.
Also, additional calories and fluids may be required for diabetic athletes and will vary based on a
myriad of factors such as: exercise intensity, total energy expenditure, type of exercise/training
program, duration of exercise, gender, dehydration, and environmental factors
Future Directions and Other Considerations
If this research were to be replicated, I would advise gathering more data over a longer
period of time. If possible, include more subjects to provide more information and determine a
greater number of, and more broadly-based recommendations. However, there is merit to
thoroughly researching one subject rather than performing mediocre research on numerous
subjects. All results and recommendations are derived and based on current peer reviewed
literature, the data collected on the individual subject, and my first-hand experience of clinically
managing a Division I NCAA athlete with type I diabetes. The fact that the subject in this case
study had tight glycemic control and was very self-sufficient in his personal management of his
type I diabetes, may limit the application of this data to a less well managed diabetic athlete
population. It is my sincere hope that this project has shed more awareness of the needs of type I
diabetics and will help athletic trainers will become better educated in the area of managing a
type I diabetic athlete.
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APPENDIX A: BLOOD GLUCOSE GRAPHS

Figure 1: Off Season Glucose Daily Sticks. This is the graph of all the manual finger sticks the
subject performed over 24 hours during a 10-day period of the off-season. Each day is represented
by a different color, and the horizontal axis represents time, and the vertical axis represents mg/dL
of blood glucose.
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Figure 2: Off Season Glucose Daily Sticks Average. This is the graph of the daily finger sticks
again, however the green line showcases the average blood glucose levels over the 10-day period.

Figure 3: Off Season Continuous Glucose Monitor Output. This graph was collected from the subject’s CGM. It shows blood glucose
readings every five minutes for 24 hours over a 10-day period during the off-season. The orange line is the average over the 10-day
period. This view shows a much more complete view of how the subject’s blood glucose trends throughout the day.
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Figure 4: Off Season Continuous Glucose Monitor Low. This graph is from the subject’s CGM again, however the point where the
subject had a significant hypoglycemic episode is highlighted.
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Figure 5: In-Season Blood Glucose Daily Sticks. This is the graph of all the manual finger sticks
the subject performed over 24 hours during a 10-day period while in-season. Each day is
represented by a different color, and the horizontal axis represents time, and the vertical axis
represents mg/dL of blood glucose.
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Figure 6: In-Season Blood Glucose Daily Sticks Average. This is the graph of the daily finger
sticks in-season again, however the green line showcases the average blood glucose levels over
the 10-day period.

Figure 7: In-Season Continuous Glucose Monitor Output. This graph was collected from the subject’s CGM. It shows blood glucose
readings every five minutes for 24 hours over a 10-day period. The yellow line is the average over the 10-day period.
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Figure 8: In-Season Continuous Glucose Monitor High. This graph is from the subject’s CGM again, however the point where the
subject had a significant hyperglycemic episode is highlighted.
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